TVM Capital Healthcare Announces Euro 10 Million Investment in DEBx Medical

23 May 2023 | Tuesday | News


DEBx Medical is innovating the management of chronic wounds, improving the life of millions of patients – the investment will enable the company to expand its global footprint and build a presence in the MENA region
Image Source : Public Domain

Image Source : Public Domain

TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, is pleased to announce an investment, from its TVM Healthcare Afiyah Fund, of EUR 10 million into DEBx Medical, an Amsterdam-based medical devices company.

DEBx Medical, founded in 2019, has developed a groundbreaking product, DEBRICHEM®, which offers a superior alternative to existing treatments for non-healing chronic wounds. This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds. With CE and ISO approvals obtained in February 2021, DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.

Chronic wounds pose a significant healthcare challenge, affecting approximately 2.4% of the population throughout their lifetime, and is particularly pronounced in the Gulf Cooperation Council (GCC) countries, where high levels of diabetes contribute to the problem. Hard-to-heal wounds have the potential for poor patient health and quality of life outcomes and represent a substantial cost to healthcare systems.

TVM Capital Healthcare's investment in DEBx Medical will enable the company to commence commercialization of its groundbreaking product for the benefit of patients. As part of the firm's investment, DEBx Medical will establish a regional headquarter and a production base in MENA, thereby accelerating the introduction of its innovative wound care solution to the region.

Tristan de Boysson, Managing Partner of TVM Capital Healthcare, commented: "With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which will transform the management of chronic wounds, and improve the life of millions of patients. This investment is also part of our Fund's strategy of bringing innovative, best-in-class healthcare solutions to the wider MENA region. We are looking forward to working together with the DEBx Medical management team."

Bert Quint, Co-founder & CEO of DEBx Medical added: "We founded the company with the aim of innovating wound care, a market that has not seen significant innovation in a very long time. Our product, DEBRICHEM®, has the potential to disrupt the chronic wound care market and help patients to heal fast, safely and effectively. After just one single treatment, more than 90% of chronic wounds start healing. TVM Capital Healthcare's investment is testament to our technology, and we are looking forward to bringing our product to market together."             

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close